Ramelteon vs Placebo for Prevention of Delirium and Improvement of Sleep in Hospitalized Older Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-01

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates whether Ramelteon can prevent delirium, decrease the severity of incident delirium and improve sleep wake cycle in hospitalized elderly surgical patients. Half of the patients will be assigned to Ramelteon, while other half will be assigned to placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery

NCT02691013

Delirium Sleep Deprivation

UNKNOWN NA

Prevention of Delirium in Inpatients Utilizing Melatonin

NCT02654314

Delirium

TERMINATED PHASE3

The Effect of Ramelteon on Delirium and Sleep in Patients Admitted to the ICU

NCT03931070

Delirium

COMPLETED PHASE4

Melatonin Supplementation for Delirium Prevention in Acutely Hospitalized Elderly

NCT00873379

Delirium

COMPLETED PHASE3

Ramelteon in the Prevention of Post-operative Delirium

NCT02324153

Delirium Delirium, Dementia, Amnestic, Cognitive Disorders Delayed Emergence From Anesthesia +1 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Delirium is a common clinical syndrome characterized by acute cognitive dysfunction with core features of inattention, disorganized thinking, perceptual disturbances and sleep-wake cycle disruption. It is typically multifactorial and can be triggered by acute infection, metabolic derangements, surgery, and certain medications. Older adults have a much higher incidence of delirium. Delirium increases in-hospital mortality, length of stay, rate of institutionalization and may cause or exacerbate cognitive impairment. The present pilot study investigates sleep loss as potentially important contributing factors in delirium and an opportunity for intervention. Sleep disruption is prevalent among hospitalized patients. Sufficient sleep is important for recovery from illness, management of pain, wound healing, and a variety of other biologic functions integral to recovery in addition to its putative role in delirium prevention. Melatonin plays an important role in circadian rhythms and sleep-wake cycle regulation. Melatonin secretion is altered in hospitalized older patients in comparison with community-living older individuals. Melatonin and the melatonin-receptor agonist Ramelteon have been studied and have shown promise in delirium prevention, in addition to promoting sleep. We propose to test the use of Ramelteon to decrease delirium and improve sleep/wake cycles in the elderly surgical patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Delirium in Old Age

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ramelteon Arm

Ramelteon tablet 8 mg orally at 21:00 for 7 days or until discharge whichever comes first.

Group Type EXPERIMENTAL

Ramelteon

Intervention Type DRUG

Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first

Placebo Arm

Sugar pill manufactured to mimic Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ramelteon

Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first

Intervention Type DRUG

Placebo

Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Rozerem

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 65 years of age or older.
* Admitted to BWH vascular surgical service.
* Able to provide informed consent or a surrogate is available to provide informed consent.
* Absence of delirium at time of consent.

Exclusion Criteria

* Expected stay or life expectancy less than 48 hours
* Unable to take medications orally
* Advanced liver disease (Child-Pugh class B or worse)
* Active treatment with Fluvoxamine
* Active treatment with antipsychotic medications, benzodiazepines or other hypnotic agents (i.e. Trazodone, Mirtazapine, Zolpidem, Zaleplon)
* Known or suspected diagnosis of Lewy body dementia
* Any dermatological condition that may be aggravated by using a wrist sensor.
* Known pre-existing sleep disorder other than insomnia.

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No